Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

被引:0
|
作者
Wojciech Krzyzanski
Elzbieta Wyska
机构
[1] University at Buffalo,Department of Pharmaceutical Sciences
[2] State University of New York,Department of Pharmacokinetics and Physical Pharmacy
[3] Jagiellonian University,undefined
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008年 / 377卷
关键词
Target-mediated drug disposition; Pharmacokinetic model; Receptor binding; Internalization;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug–receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel = 0.106 h−1 and Vc = 0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33–99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.
引用
收藏
页码:637 / 645
页数:8
相关论文
共 50 条
  • [21] Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Malhotra, Bimal
    Alvey, Christine
    Gong, Jason
    Li, Xiaoxi
    Duczynski, Gregory
    Gandelman, Kuan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 257 - 262
  • [22] The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers
    Manami Oda
    Tsutomu Kotegawa
    Kimiko Tsutsumi
    Yasukiyo Ohtani
    Keiji Kuwatani
    Shigeyuki Nakano
    European Journal of Clinical Pharmacology, 2003, 59 : 615 - 619
  • [23] Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers
    Mohrke, W
    Knauf, H
    Mutschler, E
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (10) : 447 - 452
  • [24] A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
    Rosenzweig, P
    Canal, M
    Patat, A
    Bergougnan, L
    Zieleniuk, I
    Bianchetti, G
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (01) : 1 - 13
  • [25] The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers
    Walker, Gennyne
    Mandagere, Arun
    Dufton, Christopher
    Venitz, Juergen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (05) : 527 - 534
  • [26] Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Van Hecken, A
    Depré, M
    Verbesselt, R
    Wynants, K
    De Lepeleire, I
    Arnout, J
    Wong, PH
    Freeman, A
    Holland, S
    Gertz, B
    De Schepper, PJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (05): : 495 - 500
  • [27] Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers
    B. Jansen
    U. Graselli
    S. Dallinger
    B. Kiss
    V. Wacheck
    H. Schlagbauer-Wadl
    A. Assandri
    M. Müller
    European Journal of Clinical Pharmacology, 2000, 55 : 837 - 841
  • [28] Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers
    Jansen, B
    Graselli, U
    Dallinger, S
    Kiss, B
    Wacheck, V
    Schlagbauer-Wadl, H
    Assandri, A
    Müller, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 55 (11-12) : 837 - 841
  • [29] Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers
    Cabaleiro, Teresa
    Ochoa, Dolores
    Lopez-Rodriguez, Rosario
    Roman, Manuel
    Novalbos, Jesus
    Ayuso, Carmen
    Abad-Santos, Francisco
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (05) : 459 - 469
  • [30] Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Korean Volunteers
    Jeon, Hae-Sun
    Kim, Mi-Jo
    Choi, Hee-Youn
    Kim, Yo-Han
    Kim, Eun-Hwa
    Kim, A-Reum
    Park, Hyun-Jung
    Bae, Kyun-Seop
    Lim, Hyeong-Seok
    CLINICAL THERAPEUTICS, 2015, 37 (03) : 563 - 573